STOCKS TELEGRAPH

Tag: KTRA

  • Kintara Therapeutics (KTRA) Sees Market Recovery Post Friday Downturn

    Shares of Kintara Therapeutics, Inc. (Nasdaq: KTRA) experienced a sluggish trading session on Friday, dipping nearly 5%. However, the pre-market session today hints at a slight rebound, showing a 2% increase.

    Key Corporate Updates

    Kintara, a company specializing in cancer therapies, recently unveiled significant developments:

    1. Initiation of REM-001 Study

      Kintara commenced an open-label study evaluating REM-001 in cutaneous metastatic breast cancer patients. This study, funded primarily by a $2.0 million grant from the National Institutes of Health, aims to optimize treatment protocols before moving to a Phase 3 trial.

    2. Strategic Review Underway

      The company’s Board of Directors initiated a strategic review process to enhance shareholder value, enlisting Ladenburg Thalmann & Co. Inc. as its financial advisor.

    3. Focus Shift to REM-001

      Following preliminary results from the GBM AGILE study, which indicated no significant improvement with VAL-083 in glioblastoma treatment, Kintara redirected its focus to REM-001, discontinuing the development of VAL-083.

    Financial Snapshot

    In its fiscal second-quarter results, ending December 31, 2023, Kintara reported:

    • Cash and cash equivalents of approximately $0.7 million as of December 31, 2023.
    • Net proceeds of approximately $6.1 million from the sale of common stock in early 2024.
    • A net loss of approximately $1.0 million for the three months ended December 31, 2023, attributed to lower research and development expenses and reduced general and administrative costs.

    Market Dynamics

    Recent market activity has garnered attention towards Kintara’s stock. Notable spikes in trading volume and positive indicators have piqued investor interest. The successful completion of an ATM facility, along with strengthened shareholder equity and the absence of trading constraints, further augments market sentiment.

    Conclusion

    Kintara Therapeutics navigates a dynamic market environment with strategic maneuvers and promising developments in its product pipeline. Despite encountering recent hurdles, the company’s proactive initiatives and favorable market dynamics position it for potential growth. Investors remain vigilant as Kintara advances its mission to pioneer innovative cancer therapies.

  • Kintara Therapeutics, Inc. (KTRA) stock is going down – Learn more about it!

    Kintara Therapeutics, Inc. (KTRA) stock is going down – Learn more about it!

    Kintara Therapeutics, Inc. (KTRA) has seen decrease of 1.13% in the premarket despite any news reported by the company. However, the last trading session closed at $0.354 with a decrease of 10.27%.

    Multiyear Research Grant – What’s up?

    KTRA announced on 12th January 2022 that Doctor Anna Golebiewska has been awarded with a multiyear research grant. This research grant is awarded by Luxembourg National Research Fund (FNR) and the Cancer Foundation Luxembourg. In Luxembourg, the FNR is the primary source of funding for research. Moreover, the Cancer Foundation Luxembourg is committed to patient assistance and oncology research by educating cancer patients.

    Now what?

    The acknowledgement and economic assistance from this prestigious organisation for VAL-083 research in Dr. Golebiewska’s laboratory is extremely exciting because it will offer critical data for optimising the clinical use of this first-in-class specific molecular chemotherapeutic. Furthermore, the findings of this study will aid in elucidating possible therapeutic targets for novel co – treatment regimens involving VAL-083, as well as promote the chance to improve therapeutic accuracy in GBM patients.

    First International Site Activation by KTRA – More About it

    On 30th November 2021, KTRA reported about the site activation in GCAR Phase 2/3 Clinical Trial. The speed with which the treatment arm will be implemented in the research continues to excite the Kintara team. Not only this but the company is thrilled to witness GCAR’s outstanding clinical testing consequences, which drew the team to participate in this exciting and highly efficient registrational study. With 31 sites already operational, including the first international site, the company is hopeful to observe GCAR’s extraordinary clinical trial execution capabilities.

    Through response adaptive randomization and a seamless Phase 2/3 design, GBM AGILE is a multinational, novel platform study that aims to find and confirm beneficial medicines for patients with GBM more quickly. The trial will be run under a master protocol that allows numerous medicines. Data from GBM AGILE might be utilized as the basis for new drug applicants and biologics licence applications. This has only been possible because of its novel design and efficient operational infrastructure.